Preventive & therapeutic vaccineThe advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer ...
19,20. Engineering of the RNA sequence has rendered synthetic mRNA more translatable than ever before. Highly efficient and non-toxic RNA carriers have been developed that in some cases21,22allow prolonged antigen expressionin vivo(Table 1). Some vaccine formulations...
The naked self-adjuvanted mRNA has later been applied as the mRNA vaccine for the first time in phase I/II clinical trials by intradermal injection in prostate cancer patients [30]. However, the success of the mRNA cancer vaccine has yet to be achieved because of some key challenges in ...
RNA vaccines have also been designed against herpesviruses including cytomegalovirus (CMV)107 and EBV108, and may eventually be a promising vaccine platform for KSHV in the future should costs of manufacturing decrease. As with SARS-CoV-2 mRNA vaccines, thermostability for a KSHV mRNA vaccine might...
Researchers have been experimenting with mRNA for decades as a potential weapon against cancer, but they haven't had much luck -- until now. In a new study, scientists tested two groups of melanoma patients. They found nearly 79% of patients had no recurrence after 18 months when given a ...
It is hypothesized that most or all of the viral proteins that transcribe NDV mRNA also carry out their replication. The mechanism that regulates the alternative uses (i.e., transcription or replication) of the same complement of proteins has not been clearly identified but appears to involve th...
[18]. In general, cancer vaccines are designed to target tumor-associated or tumor-specific antigens (TAAs or TSAs). A vaccine with an mRNA sequence encoding a TSA or TAA can direct the immune system to recognize the antigen and thereby prevent cancer spread by killing the antigen-...
“The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies,” added Ugur Sahin, MD, CEO and Co-Founder of BioNTech. “Adults aged 50 years and older as well as vulnerable populations like cancer patients are...
mRNA vaccine;circular RNA vaccine;saRNA vaccine;infectious diseases;drug delivery system 1. Introduction 1.1. Conventional mRNA Vaccine Over the past few decades, mRNA vaccine development has achieved significant milestones since the discovery of mRNA in 1961 [1]. Within eight years, the successful pr...
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med, 384 (2021), pp. 403-416, 10.1056/nejmoa2035389 View in ScopusGoogle Scholar [89] WHO Background document on the mRNA vaccine WHO (2021) 2 Google Scholar [90] T. Shimabukuro Allergic reactions including anaphylaxis af...